| Source: |
Verreck, E E F, Kuijer, A, van Steenhoven, J E C, Volders, J H, van der Velden, A W G, Siesling, S, Timmer-Bonte, A N H, Smilde, T J, Imholz, A L T, Blanken-Peeters, C F J M, de Valk, B, Vrijaldenhoven, S, Lastdrager, W B, Haringhuizen, A W, Hunting, J C B, Hovenga, S, Nieboer, P, Zuetenhorst, H M, Tetteroo, G W M, Smorenburg, C H, van Maaren, M C & van Dalen, T 2025, '70-Gene signature-guided adjuvant systemic treatment adjustments in early-stage ER+ breast cancer patients : 7-year follow-up of a prospective multicenter cohort study', Breast Cancer .... |
| Description: |
Background: A previous prospective multicenter study revealed the change of the oncologists’ chemotherapy advice due to the 70-Gene signature (GS) test result in half of the estrogen receptor-positive (ER+) invasive early-stage breast cancer patients with disputable chemotherapy indication. This resulted in less patients receiving chemotherapy. This study aims to complement these results by the 7-year oncological outcomes according to the 70-GS test result and the oncologists’ pre-test advice. Methods: Patients operated for early-stage ER+ breast cancer with disputable chemotherapy indication, had been prospectively included between 2013 and 2015. Oncologists were asked whether they intended to administer adjuvant chemotherapy before deployment of the 70-GS test. Information on adjuvant systemic treatment and oncological outcome was obtained through active follow-up by data managers of the Netherlands Cancer Registry. The primary endpoint of this study was distant metastasis-free survival (DMFS) according to the genomic risk. Exploratory analyses were done to evaluate DMFS in relation to the oncologists’ pre-test advice. Results: After a median follow-up of 7 years, distant metastases were diagnosed in 23 of the 606 patients (3.8%) and 36 (5.9%) patients had died. The DMFS rate for the 357 70-GS genomic low-risk patients was 94.2% (95% CI 91.2–96.2) and 89.1% for the 249 genomic high-risk patients (95% CI 84.3–92.4). Of the low-risk patients 3% had received chemotherapy compared to 80% of the high-risk patients. For the subgroups based on the pre-test oncologists’ advice (no chemotherapy/chemotherapy/unsure) there were no clinically relevant differences in DMFS (89.8, 93.2 and 92.0%, respectively), while comparable proportions of patients had received chemotherapy. Conclusions: In patients with early-stage ER+ breast cancer with a disputable chemotherapy indication it is sensible to deploy the 70-GS to better select patients for adjuvant chemotherapy. |